Grünenthal GmbH

Privately held: no public share price

Assets

(4 total)
4Total Assets
3Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule
Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathy
Esomeprazole(Nexium)
Approved
H+/K+-ATPase (gastric proton pump)Small molecule
Helicobacter pylori Infection
Approved
Mu-opioid receptor and norepinephrine transporter (NET)Small molecule
Diabetic Peripheral Neuropathic PainNeuropathic Pain
Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain
Phase 3
Mesenchymal precursor cells (MPCs)Cell therapy
Heart FailureChronic Low Back Pain

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
rexlemestrocel-LPhase 3Degenerative Disc Disease
Est. primary completion 2027-07 · NCT06325566 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026PresentationCapsaicin (Qutenza)Phase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)
30 June 2026Filing submittedrexlemestrocel-LMesoblast received a BLA filing number and requested modular review for rexlemestrocel-L in LVAD patients
US, FDA · Source ↗
December 2025ApprovalTapentadolFDA updates Boxed Warning on Tapentadol (NDA200533)
US, FDA · FDA · Source ↗
23 May 2024WithdrawalZolmitriptan (Zomig)FDA withdraws approval of NDA 020768 (Federal Register 2024-08657)
US, FDA · Source ↗

Financial reports

No financial reports recorded.